Taysha Gene Therapies, Inc. (TSHA) Key Metrics
TSHA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.18B
- Enterprise value
- $1.20B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 215.0 10-yr median 51.9
- Price / book
- 4.1 10-yr median 6.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.17
TSHA key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTSHA valuation Price multiples at each fiscal year-end price.
TSHA returns How much profit the business earns on the capital it uses.
TSHA per-share figures Results divided by the shares outstanding at year-end.
TSHA financial health Debt, liquidity and how easily interest is covered.
TSHA efficiency & capital use Working capital cycle and where the cash goes.
TSHA valuation history
TSHA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TSHA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TSHA price vs earnings per share
TSHA key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $1.76B | $432.7M | $205.5M | — | — | — | — |
| Enterprise value | $1.46B | $356.9M | $122.7M | — | — | — | — |
| Price / sales | 179.9 | 51.9 | 13.3 | — | — | — | — |
| Price / book | 7.1 | 6.1 | 2.7 | — | — | — | — |
| EV / sales | 149.1 | 42.8 | 7.9 | — | — | — | — |
| Earnings yield | −6.2% | −20.6% | −54.3% | — | — | — | — |
| Free cash flow yield | −5.3% | −18.9% | −39.1% | — | — | — | — |
| Share price at fiscal year-end | $5.50 | $1.73 | $1.77 | $2.26 | $11.65 | $26.54 | — |
| Per share | |||||||
| Revenue per share | $0.03 | $0.03 | $0.13 | — | — | — | — |
| Earnings per share | −$0.34 | −$0.36 | −$0.96 | — | — | — | — |
| Operating cash flow per share | −$0.29 | −$0.32 | −$0.63 | — | — | — | — |
| Free cash flow per share | −$0.29 | −$0.33 | −$0.69 | — | — | — | — |
| Cash per share | $1.00 | $0.56 | $1.24 | — | — | — | — |
| Book value per share | $0.77 | $0.29 | $0.65 | — | — | — | — |
| Tangible book value per share | $0.77 | $0.29 | $0.65 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.06 | — | — | — | — |
| Debt per share | $0.06 | $0.25 | $0.53 | — | — | — | — |
| Shares outstanding | 319.7M | 250.1M | 116.1M | — | — | — | — |
| Change in shares outstanding | +27.8% | +115.4% | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −68.5% | −121.9% | −294.0% | −344.7% | −100.7% | −34.2% | — |
| Return on assets (ROA) | −43.3% | −53.6% | −74.6% | −97.6% | −73.8% | −33.2% | — |
| Return on tangible assets | −31.7% | −55.7% | −64.6% | −131.5% | −81.6% | −16.6% | — |
| Free cash flow margin | −960.1% | −979.2% | −520.3% | — | — | — | — |
| Financial health | |||||||
| Total debt | $18.2M | $63.2M | $61.1M | $59.9M | $63.1M | — | — |
| Cash & short-term investments | $319.8M | $139.0M | $143.9M | $87.9M | $149.1M | $251.3M | — |
| Net debt | −$301.6M | −$75.9M | −$82.8M | −$28.0M | −$86.0M | −$251.3M | — |
| Debt / equity | 0.07 | 0.88 | 0.82 | 63.15 | 0.66 | — | — |
| Debt / assets | 0.05 | 0.39 | 0.35 | 0.47 | 0.29 | — | — |
| Current ratio | 12.23 | 5.42 | 4.08 | 1.54 | 3.08 | 36.17 | 0.10 |
| Quick ratio | 12.23 | 5.42 | 4.08 | 1.54 | 3.08 | 36.17 | 0.10 |
| Interest coverage | — | -896.7 | -14.5 | -33.2 | -121.3 | — | — |
| Working capital | $298.1M | $115.9M | $113.1M | $33.6M | $107.9M | $250.8M | −$135,000 |
| Invested capital | −$54.7M | −$4.3M | −$7.9M | −$27.0M | $9.4M | $49,000 | −$135,000 |
| Tangible asset value | $246.9M | $71.5M | $74.9M | $949,000 | $95.4M | $251.3M | −$135,000 |
| Net current asset value | $228.3M | $53.3M | $52.1M | −$28.9M | $41.0M | $250.3M | −$135,000 |
| Graham net-net per share | $0.70 | $0.20 | $0.40 | — | — | — | — |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | — | — | $0 | — |
| Capex / revenue | 7.6% | 4.5% | 47.7% | 994.0% | — | — | — |
| Capex / operating cash flow | — | — | — | — | — | — | 60.7% |
| Capex / depreciation | 0.64 | 0.30 | 5.37 | 21.22 | 43.81 | 1,009.11 | 0.02 |
| Stock-based compensation / revenue | 136.1% | 157.2% | 51.2% | 721.1% | — | — | — |
| R&D / revenue | 884.1% | 792.0% | 367.5% | 3,643.8% | — | — | — |
| SG&A / revenue | 346.5% | 347.4% | 203.3% | 1,493.2% | — | — | — |
| Efficiency | |||||||
| Days payables outstanding | 1,572.7 | 1,459.7 | 2,304.5 | 2,400.2 | 8,812.3 | 80,867.8 | — |
| Payables turnover | 0.23 | 0.25 | 0.16 | 0.15 | 0.04 | 0.00 | — |
| Asset turnover | 0.04 | 0.05 | 0.10 | 0.01 | 0.00 | 0.00 | 0.00 |
| Average payables | $4.9M | $5.0M | $8.7M | $16.4M | $11.9M | $2.0M | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TSHA's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TSHA valuation and financial ratios
Taysha Gene Therapies earned a return on equity of −68.5% in fiscal 2025. It ended the year with $18.2 million of debt and $319.8 million in cash and short-term investments, a net cash position of $301.6 million.
See the TSHA income statement, the TSHA chart for price history, or the TSHA stock overview for the latest quote and news.
TSHA key metrics FAQ
What is Taysha Gene Therapies's return on equity?
Taysha Gene Therapies's return on equity (ROE) was −68.5% in fiscal 2025: net income of -$109.0 million on average shareholders' equity of $159.2 million.
How much debt does Taysha Gene Therapies have?
Taysha Gene Therapies had total debt of $18.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.07 and more cash than debt.
What is Taysha Gene Therapies's free cash flow yield?
Taysha Gene Therapies generated -$93.8 million of free cash flow in fiscal 2025, a free cash flow yield of −5.3% on its market value at year-end ($1.8 billion).
What is Taysha Gene Therapies's current ratio?
Taysha Gene Therapies's current ratio was 12.23 at the end of fiscal 2025: current assets were 12.23 times current liabilities.